Coming October 29: SITC releases its late-breaking abstract titles. We’ll add their presenting authors’ institutions to this guide once they’re out.

Genentech at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

Genentech brings 2 presentations to SITC 2026 in Phoenix. Its program centres on why some tumors resist immunotherapy and how to tune T cell responses. One study links faulty tertiary lymphoid structures tied to TGF-beta to a resistant group of bladder cancers, and another uses IL-27 to balance tumor attack against side effects.

Organization	SITC 2026 Attendance
Genentech South San Francisco, CA
gene.com Large pharma Roche's US biotechnology arm, developer of the PD-L1 antibody atezolizumab and other cancer medicines.	Talk Sat Nov 7 10:40am–10:55am Part of Session 202: Spatial Biology TGFβ-Associated TLS dysfunction defines an immunotherapy-resistant subgroup in bladder cancer Halls BC Tumor biology Poster Sat Nov 7 12:30–1:30pm 6:40–8:10pm Sculpting T Cell Responses with IL-27 to balance Anti-Tumour Immunity and Toxicity Exhibition Halls 4-6 · Poster 1044 New agents · Tumor biology

Instantly find 20 buyers from Genentech

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the Society for Immunotherapy of Cancer (SITC). Submit a correction